Topics:

Renal Cell Carcinoma

Expression of BAP1 could help identify which clear-cell renal cell carcinoma patients diagnosed with low-risk disease are the most likely to progress.

Renal Cell Carcinoma

A study of patient preference revealed that patients who participated in a crossover trial of pazopanib and sunitinib for metastatic renal cell carcinoma preferred treatment with pazopanib.

Ball-and-stick model of sunitinib

Patients receiving treatment with sunitinib for advanced renal cell carcinoma experienced worse treatment-related fatigue during the first cycle of treatment with symptoms lessening after subsequent consecutive cycles.

A history of significant cigarette smoking adversely affected overall survival in patients who underwent surgery for clear-cell renal cell carcinoma, according to the results of a recent study.

The FGF inhibitor dovitinib failed to improve progression-free survival outcomes as a third-line treatment for patients with metastatic renal cell carcinoma compared with sorafenib, according to the results of a new study.

New research shows that tumors found in obese patients may be more indolent than those in nonobese patients, and this may, in part, be related to alterations in fatty acid metabolism explaining the obesity paradox in clear-cell renal cell carcinoma.

The order of the sequencing of sorafenib and sunitinib for first-line and second-line therapy did not affect progression-free and overall survival for patients with advanced renal cell carcinoma.

The use of angiotensin system inhibitors significantly improved the survival of patients with metastatic RCC who were on the drug for the treatment of hypertension, according to the results of a retrospective study presented at the ASCO GU Symposium.

Pages

Subscribe to
Please Wait 20 seconds or click here to close